Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer | OncLive

Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer

May 2, 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

Naumann presented data from a phase 1 dose-escalation trial (NCT03748186) with STRO-002 in patients with platinum-resistant/refractory ovarian cancer during the 2020 AACR Virtual Annual Meeting I. Patients received a median of 5 prior lines of therapy, representing a heavily pretreated population, says Naumann. Investigators evaluated 7 doses, ranging from 0.5 mg/kg to 6.0 mg/kg. The recommended phase 2 dose has not yet been determined.

To date, investigators have reported several CA-125 responses and 1 partial response, says Naumann. Moreover, the majority of patients have participated in the trial for more than 24 weeks, suggesting that the agent is well tolerated.


x